News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
436 Results
Type
Article (21)
Company Profile (1)
Press Release (414)
Section
Business (119)
Deals (15)
Drug Development (127)
FDA (6)
Job Trends (9)
News (261)
Policy (27)
Tag
Alliances (19)
Alzheimer's disease (3)
Approvals (6)
Best Places to Work (4)
Biotechnology (1)
Cell therapy (1)
Clinical research (108)
Collaboration (1)
COVID-19 (1)
C-suite (1)
Depression (2)
Diagnostics (1)
Earnings (43)
Events (52)
Executive appointments (3)
FDA (7)
Funding (1)
GLP-1 (1)
Healthcare (3)
Infectious disease (1)
Intellectual property (1)
IPO (10)
Job creations (5)
Layoffs (4)
Legal (1)
Manufacturing (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (5)
Neuroscience (5)
NextGen: Class of 2026 (9)
Patient recruitment (1)
People (50)
Phase 1 (13)
Phase 2 (64)
Phase 3 (42)
Pipeline (5)
Postmarket research (4)
Preclinical (13)
Rare diseases (1)
Real estate (1)
Regulatory (28)
Series B (1)
Startups (4)
Vaccines (3)
Date
Last 365 days (13)
2026 (3)
2025 (10)
2024 (10)
2023 (20)
2022 (21)
2021 (30)
2020 (37)
2019 (39)
2018 (7)
2017 (22)
2016 (18)
2015 (24)
2014 (24)
2013 (38)
2012 (35)
2011 (31)
2010 (27)
Location
Asia (16)
Australia (3)
California (2)
China (1)
Europe (39)
Massachusetts (12)
Nevada (1)
Pennsylvania (2)
South America (1)
Southern California (2)
United States (16)
436 Results for "cyclerion therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
September 23, 2025
·
7 min read
Press Releases
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
January 6, 2026
·
9 min read
Press Releases
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
December 18, 2024
·
4 min read
Business
Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Therapeutics, Inc. today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately.
December 4, 2023
·
5 min read
Business
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Cyclerion Therapeutics, Inc., a biopharmaceutical company on a mission to develop treatments for serious diseases, announced the appointments of Dina Katabi, Ph.D., and Michael Higgins to its Board of Directors.
November 30, 2023
·
5 min read
Genetown
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - June 01, 2023
Cyclerion Therapeutics, Inc. announced that it has received a formal notice from The Nasdaq Stock Market stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550, and that Cyclerion is in compliance with all applicable listing standards.
June 1, 2023
·
2 min read
Genetown
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
Cyclerion Therapeutics, Inc. announced that it has signed a definitive agreement with a new private company to sell two of its sGC stimulator assets in exchange for cash and equity ownership.
May 11, 2023
·
5 min read
Business
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates and first quarter 2023 financial results.
May 11, 2023
·
9 min read
Genetown
Cyclerion Announces Reverse Stock Split - May 15, 2023
Cyclerion Therapeutics, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 5:00 p.m. Eastern Time on May 15, 2023.
May 15, 2023
·
5 min read
Genetown
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program.
March 22, 2023
·
6 min read
1 of 44
Next
